<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01910844</url>
  </required_header>
  <id_info>
    <org_study_id>CJP 4.2 - META2</org_study_id>
    <nct_id>NCT01910844</nct_id>
  </id_info>
  <brief_title>Phase II Pilot Study Assessing Efficacy of a Cisplatin - Métronomic Cyclophosphamide Treatment in Patients With Stade IV Triple Negative Breast Cancer Secondary Resistant to Anthracyclines and Taxanes</brief_title>
  <acronym>META2</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Jean Perrin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Jean Perrin</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study assessing efficacy of a Cisplatine- Métronomic cyclophosphamide treatment in Patients
      with Metastatic Triple Negative breast Cancer Secondary Resistant to Anthracyclines and
      Taxanes.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Because of difficulties in recruting
  </why_stopped>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate of cisplatine - metronomic cyclophosphamide treatment</measure>
    <time_frame>12 months and 6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease free progression</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile of cisplatin - metronomic cyclophosphamide association</measure>
    <time_frame>12 months and 6 weeks</time_frame>
    <description>Number of Participants with Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictive factors to response and/or resistance treatment</measure>
    <time_frame>12 months and 6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Cisplatin - Metronomic Cyclophosphamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cisplatin 25 mg/m² from day 1 to day 3 every 3 weeks Metronomic Cyclophosphamide 150 mg from day 1 to day 14 every 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>25 mg/m² I.V. from day 1 to day 3 - total dose = 75 mg/m² every 3 weeks</description>
    <arm_group_label>Cisplatin - Metronomic Cyclophosphamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Metronomic cyclophosphamide per os 150 mg from day 1 to day 14 - total dose 2100 mg every 3 weeks</description>
    <arm_group_label>Cisplatin - Metronomic Cyclophosphamide</arm_group_label>
    <other_name>Endoxan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Performance status &lt; 2,

          -  Patient with metastatic breast cancer stade IV triple negative histologically
             confirmed

          -  Measurable or not disease but radiologically evaluable (RECIST 1.1),

          -  Negative Hormonal Receptors (Estrogens and/or Progesterone),

          -  HER-2 negative (Score 0 or 1 by Immunochemistry (IHC), negative FISH if score IHC 2),

          -  Patient exposed to anthracyclines and/or taxanes in neo-adjuvant or adjuvant setting,

          -  Patient with a progression and for whom anthracyclines and/or taxanes treatment cannot
             be delivered and according to a resistance defined as :

          -  In the last 12 months after the last dose of taxanes or anthracyclines in adjuvant or
             neoadjuvant setting or,

          -  During or after a first metastatic chemtotherapy line and where taxanes and
             anthracyclines cannot be delivered according to :

          -  either a secondary resistance after an initial response to chemotherapy but a relapse
             observed either during the treatment or in the 4 months after the end of chemotherapy.

          -  either a sensitivity to treatment defined by a relapse after more than 4 months after
             the first chemotherapy metastatic line,

          -  either intolerance to anthracyclines (doxorubicin 240-400 mg/m² ou equivalent to
             doxorubicin (epirubicin) 300-550mg/m²)

          -  Patient non previously treated by platinum salts,

          -  Hematological Functions: Neutrophiles ≥ 1,5.109/L, Platelets ≥ 100.109/L, Leucocytes &gt;
             3 000/mm3, Hb &gt; 9g/dL, Hepatic Functions : total Bilirubin ≤ 1,5 time upper normal
             value (UNV), ASAT ≤ 2 ,5 time UNV, ALAT ≤ 2,5 time UNV, Alkaline Phosphatase ≤ 2,5
             time UNV (&lt; 5 time UNV if case of hepatic metastasis), Renal Functions: Serum
             Creatinine ≤ 1,5 time UNV (and if value &gt; 1,5 time UNV, so Clearance ≥ 60 mL/min) or
             Clearance ≥ 40 mL/min in case of RMI,

          -  Patient signed the consent study form,

          -  Patient affiliated to a social security regimen (law of 9 August 2004).

        Exclusion Criteria:

          -  Male Patients,

          -  Unknown hormonal Receptors

          -  Positive HER-2 (Score 3 in IHC or positive FISH)

          -  Pregnant or breastfeeding patient, or in age of pregnancy or predicting to be pregnant
             in the 6 months after the end of treatment,

          -  Patient not using contraceptive treatment during the treatment or after the 6 months
             after the end of treatment,

          -  Patient is a ward,

          -  Patient suffering from a non compatible disease with the enrollment in the study,

          -  Cardiac, renal, medullar, respiratory or hepatic insufficiency, clinically significant
             cardiovascular disease (including myocardiac infarct, unstable angina, symptomatic
             congestive heart failure, uncontrolled cardiac arrhythmia) &lt; 1 year before the study
             enrollment or randomisation,

          -  Patient with pulmonary lymphangitis or symptomatic pleural effusion (grade≥2),
             meningeal known carcinoma or symptoms of cerebromeningeal invasion, brain metastases
             unless treatment and stability for at least 4 weeks (no steroids or anti-convulsive).

          -  Uncontrolled diabetes,

          -  Psychiatric or neurological significant abnormality,

          -  Peripheric Neuropathy &gt; grade 2,

          -  Antecedent of hypersensibility to one of study treatment or one of used excipients,

          -  Urinary tract infection or acute hemorrhagic cystitis in progress

          -  Concomitant treatment with a medicine containing phenytoin or medication received in
             the context of a trial, or participation in another therapeutic clinical trial within
             &lt;30 days prior treatment with chemotherapy.

          -  Geographically unstable patient in the next 6 months or remaining distance to the
             treatment center making it difficult to follow in the study,

          -  Known history of abuse of narcotic or other drug or alcohol

          -  History of surgery within 28 days before the start of treatment,

          -  Patient unwilling or unable to comply with the requirements of the study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 28, 2013</study_first_submitted>
  <study_first_submitted_qc>July 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2013</study_first_posted>
  <last_update_submitted>October 10, 2016</last_update_submitted>
  <last_update_submitted_qc>October 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>triple negative breast cancer</keyword>
  <keyword>late-relapse</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

